Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

In a phase 3 trial among patients who were unvaccinated and not hospitalised, paxlovid was shown to reduce the risk of hospitalisation or death by 89%.2 However, evidence on paxlovid in high-risk patients who are immunocompromised is in short supply.3 A paxlovid registry study was done in Shanghai Renji Hospital South Campus, a COVID referral centre from April 7, 2022, to May 7, 2022, with institutional review board approval and informed consent obtained from all participants. There were 35 patients who were immunocompromised in our cohort, including three recipients of solid organ transplants, seven with autoimmune rheumatic conditions, three with haematological malignancies, and 22 with malignant solid tumours. In summary, this real-life study in Chinese patients with SARS-CoV-2 infection called for action to implement early treatment of paxlovid for high-risk patients who are immunocompromised,5 including those who are hospitalised, and unvaccinated in particular, in order to facilitate viral eradication.